Voya Investment Management LLC Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Voya Investment Management LLC lessened its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 52.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 676,353 shares of the biopharmaceutical company's stock after selling 743,492 shares during the period. Voya Investment Management LLC owned about 0.23% of Amicus Therapeutics worth $6,371,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Covestor Ltd lifted its position in shares of Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 2,312 shares during the last quarter. R Squared Ltd bought a new stake in shares of Amicus Therapeutics during the 4th quarter worth about $79,000. KBC Group NV grew its stake in Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 3,120 shares during the last quarter. Sciencast Management LP acquired a new stake in Amicus Therapeutics during the fourth quarter worth approximately $100,000. Finally, Stephens Inc. AR bought a new stake in shares of Amicus Therapeutics during the fourth quarter worth approximately $101,000.

Amicus Therapeutics Trading Down 0.1 %

Amicus Therapeutics stock traded down $0.01 during trading hours on Friday, hitting $6.67. The stock had a trading volume of 6,371,892 shares, compared to its average volume of 2,687,112. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of -37.06, a P/E/G ratio of 1.51 and a beta of 0.79. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The business's 50 day simple moving average is $7.95 and its 200-day simple moving average is $9.30. Amicus Therapeutics, Inc. has a one year low of $6.20 and a one year high of $12.65.

Analyst Ratings Changes

FOLD has been the subject of several recent research reports. The Goldman Sachs Group reduced their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. UBS Group raised their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday. Wells Fargo & Company reduced their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Finally, StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.